Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 19, 2026

Stock market today: Dow, S&P 500, Nasdaq slip as oil prices continue rally amid Iran-US tensions

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq slip as oil prices continue rally amid Iran-US tensions US stocks retreated on Thursday as US-Iran fears spurred a continued rally in oil, with Walmart (WMT) earnings and Federal Reserve rate-cut odds in focus…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 looks like the bottom of the cycle for Deere

    80% confidence

  • President Trump said he would decide on whether to strike Iran within the next 10 days

    80% confidence

  • Talks between Tehran and Washington had reached a potential framework for a deal on Iran's nuclear program

    80% confidence

  • The Federal Reserve is pretty close to neutral on where monetary policy is at current 3.5% to 3.75% target range

    80% confidence

  • The VIX is not a fear gauge, it just plays one on TV - it's more a read on hedging demand for 30-day S&P options

    80% confidence

  • If you don't have the backbone, go invest in some boring bond (regarding bitcoin volatility)

    80% confidence

  • Company was encouraged by the ongoing recovery in demand within both the construction and small agriculture segments

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq slip as oil prices continue rally amid Iran-US tensions — Source | Via News | Finance Via News